TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00059345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture treatments provided two times per week for 6 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture treatments provided 2 times per week for 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care for knee osteoarthritis
Study: NCT01584310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire STAMP and dietary
Description: Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No STAMP using
Description: No intervention
Study: NCT03655041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: Beta-alanine in sustained-release tablets to increase muscle carnosine content
Study: NCT01458535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules
Study: NCT03655041

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
Study: NCT03400826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mg
Description: The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
Study: NCT01669486

Intervention type: OTHER
Intervention: CPOT, BPS
Description: Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
Study: NCT02691559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic fluid analysis by blood gas device
Description: Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic fluid analysis by blood gas device
Description: Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
Study: NCT02414685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study: NCT02414685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study: NCT03667781

Intervention type: DIAGNOSTIC_TEST
Intervention: Therapeutic drug monitoring
Description: Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
Study: NCT02414685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
Study: NCT02396212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
Study: NCT02346175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02470520

Intervention type: PROCEDURE
Intervention: CRRT
Description: continuous renal replacement therapy
Study: NCT02883803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of mesenchymal stem cells
Description: Injection of mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Injection of albumin alone
Description: Injection of albumin alone
Study: NCT02133898

Intervention type: OTHER
Group type: OTHER
Intervention: L-methylfolate
Description: L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
Study: NCT03703544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic index
Description: Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
Study: NCT01561235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose-reponse effect of protein on appetite and appetite-regulating hormones
Description: 3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose-reponse effect of protein on appetite and appetite-regulating hormones
Description: 3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose-reponse effect of protein on appetite and appetite-regulating hormones
Description: 3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
Study: NCT04579341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: probiotics administration
Study: NCT03869554

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of Fabry disease
Description: Systematic detection of Fabry disease
Study: NCT00679835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
Study: NCT01721863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
Study: NCT02591940

Intervention type: PROCEDURE
Intervention: Surgery or Treatment by Heart Catheter

Intervention type: PROCEDURE
Intervention: Surgery or Treatment by Heart Catheter
Study: NCT04508426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AR882
Description: Single dose of \[14C\]AR882
Study: NCT01362348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: 10 mg/mL (1 drop) four times daily
Study: NCT01534000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac computed tomographic angiography (CCTA)
Description: Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
Study: NCT05254106

Intervention type: DEVICE
Intervention: Lower limb artery revascularization with paclitaxel-eluting device
Description: Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon
Study: NCT02535143

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test Cavity Preparation
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cavity Preparation
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Description: 250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post intervention test cavity
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post intervention test cavity
Description: Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbonated Apple Juice
Description: 250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
Study: NCT03349658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: effect of general anesthesia on transcranial regional cerebral oxygen saturation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
Study: NCT03062514

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PINS Vagus Nerve Stimualtor
Description: PINS Vagus Nerve Stimualtor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Vagus Nerve Stimualtor
Description: PINS Vagus Nerve Stimualtor
Study: NCT03196544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Approach Training (5 sessions)
Description: 5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Approach Training (10 sessions)
Description: 10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
Study: NCT04314986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT01135147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary therapy and physical education

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Adenotonsillectomy along with diet and physical therapy
Study: NCT04314986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 3: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT01340807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized Functional Prosthetic Training
Description: Each subject receives specialized functional prosthetic training
Study: NCT02461407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT03951701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the supportive care
Description: Evaluation of interest of a systematic screening for oncological supportive care needs
Study: NCT04293601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interventional nursing care
Description: The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) \> 32 weeks (wks)~* Current weight \> 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration \> 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift

Intervention type: OTHER
Group type: OTHER
Intervention: Standard nursing care
Description: * Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases
Study: NCT00912756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 200 mg/day BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 200 mg/day BID
Study: NCT01587807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057
Description: inhaled dose (volume based on cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057
Description: inhaled dose (volume based on cohort)
Study: NCT00893880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% gaseous Nitric Oxide blended in Oxygen
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% gaseous Nitric Oxide blended in Oxygen
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% gaseous Nitric Oxide blended in Oxygen
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% gaseous Nitric Oxide blended in Oxygen
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
Study: NCT04314986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 4: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study: NCT00947271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 1
Description: The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 1
Description: The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 2
Description: The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 2
Description: The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
Study: NCT01587807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057
Description: inhaled dose (volume based on cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057
Description: inhaled dose (volume based on cohort)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: BAL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: 50 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
Study: NCT04112966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 14 sessions of manual lymphatic drainage technique
Description: Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the health education
Description: The health education for lymphedema prevention.

Intervention type: OTHER
Group type: OTHER
Intervention: the health education
Description: The health education for lymphedema prevention.
Study: NCT04064749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
Study: NCT01006031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and Ribavirin
Description: Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels.
Study: NCT03353025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transsphenoidal surgery treatment
Description: transsphenoidal surgery treatment
Study: NCT01864343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMCOOLS flex pad; Philips Innercool RTx
Description: Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
Study: NCT02741635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Nasal Pillows Mask
Description: Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
Study: NCT02289638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-Laryngoscopy
Study: NCT02085018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo
Study: NCT01633541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: Patients will receive AT-101 40 mg orally two times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Taxotere) 75 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg